Inmune Bio (INMB) Accounts Payables (2017 - 2026)
Inmune Bio (INMB) posted Accounts Payables of $4.7 million for Q1 2026, down 40.02% sequentially from $7.8 million in Q4 2025, and down 35.27% YoY from $7.2 million in Q1 2025.
Inmune Bio (INMB) Accounts Payables (2017 - 2026) Analysis & Trends
Inmune Bio has reported Accounts Payables for 10 years, with the latest figure at $4.7 million in Q1 2026.
- Quarterly Accounts Payables fell 35.27% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 35.27% YoY) and the FY2025 annual result came in at $7.8 million, up 18.79% from the prior year.
- Accounts Payables fell to $4.7 million in Q1 2026 per INMB's latest filing, from $7.8 million in the prior quarter.
- Over five years, Accounts Payables peaked at $10.6 million in Q3 2024 and troughed at $25000.0 in Q3 2025.
- A 5-year average of $5.2 million and a median of $5.2 million in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 1462.5% in 2022, then tumbled 99.76% in 2025.
- Over 5 years, Accounts Payables stood at $5.2 million in 2022, then surged by 51.77% to $7.9 million in 2023, then slipped by 17.24% to $6.5 million in 2024, then grew by 18.79% to $7.8 million in 2025, then sank by 40.02% to $4.7 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $4.7 million, $7.8 million, and $25000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 5.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.05 Mn |
| Mar 31, 2026 | 4.66 Mn |
| Dec 31, 2025 | 7.77 Mn |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 7.67 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Dec 31, 2024 | 6.54 Mn |
| Sep 30, 2024 | 10.59 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Mar 31, 2024 | 9.29 Mn |
| Dec 31, 2023 | 7.90 Mn |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 726,000.00 |
| Mar 31, 2023 | 2.08 Mn |
| Dec 31, 2022 | 5.21 Mn |
| Sep 30, 2022 | 3.47 Mn |
| Jun 30, 2022 | 375,000.00 |
| Mar 31, 2022 | 2.55 Mn |
| Dec 31, 2021 | 3.73 Mn |
| Sep 30, 2021 | 4.22 Mn |